Evidence map›Paper›PMID 41648038›Full record

ArticleESMO gastrointestinal oncology2024

HER2-directed therapy following ctDNA-identified

S Chakrabarti, L Bucheit, J Saha, K Clemens, R Barnett, N Zhang, A Mahipal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO gastrointestinal oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

S ChakrabartiUniversity Hospitals Seidman Cancer Center, Case Western Comprehensive Cancer Center, Cleveland.
L BucheitMedical Affairs and Outcomes and Evidence, Guardant Health, Redwood City, USA.
J SahaMedical Affairs and Outcomes and Evidence, Guardant Health, Redwood City, USA.
K ClemensMedical Affairs and Outcomes and Evidence, Guardant Health, Redwood City, USA.
R BarnettMedical Affairs and Outcomes and Evidence, Guardant Health, Redwood City, USA.
N ZhangMedical Affairs and Outcomes and Evidence, Guardant Health, Redwood City, USA.
A MahipalUniversity Hospitals Seidman Cancer Center, Case Western Comprehensive Cancer Center, Cleveland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Data on patient outcomes with human epidermal growth factor receptor 2 (HER2)-directed therapy after detection of Materials and methods: Real-world evidence was sourced from the GuardantINFORM (Guardant Health) database which includes aggregated health claims and de-identified results from patients undergoing ctDNA testing [Guardant360 (G360)]. Patients with aGEA, Results: We identified 215 patients with Conclusions: Detection of

Indexed as

ctDNAERBB2gastroesophagealliquid biopsyreal-world evidence (RWE)

Identifiers

PMID41648038
PMCPMC12836549

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.